This report - which is available individually or as part of a full subscription to Global PV Tracker - examines the trends and opportunities in patient caseloads and procedure volumes in stereotactic radiosurgery markets.
Stereotactic radiosurgery is a non-invasive radiation therapy procedure performed for treatment of a variety of tumor types as well as certain types of vascular and neurological abnormalities. Stereotactic radiosurgery employs three-dimensional imaging techniques such as CT and MRI to precisely locate the tumor or abnormality within the body combined with gamma or x-ray irradiation with focused beams. The technology enables highly selective ablation of a tumor or abnormality while minimizing damage to adjoining healthy tissue. Stereotactic radiosurgery is used in the treatment of small brain tumors; other types of tumors including tumors in the lung, spine, prostate, liver, head and neck, and abdomen; and in the treatment of arteriovenous malformations in the brain as well as certain neurological disorders such as trigeminal neuralgia. In 2017, the number of stereotactic radiosurgery procedures performed worldwide totaled approximately 480,000. The number of procedures per year is forecast to grow at an 11.7% compound annual rate over the 2017-2022 interval, with volume exceeding 830,000 by 2022. The rate of growth is significantly greater than the growth rate for the combined population of the 37 countries analyzed in this report of 0.7% per year, as well as the growth rate for incidence of central nervous system cancer in the combined countries of 2.2% per year.
QUESTIONS ANSWERED IN THIS REPORT:
DATABOOK: Buyers of this report also receive an Excel dashboard containing stereotactic radiosurgery procedure forecasts segmented by global, region (4) and country (32).
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
